Group 1: Market Developments - Shenzhen aims to exceed a total market capitalization of 20 trillion yuan for listed companies by the end of 2027, an increase of 5 trillion yuan from previous targets [1] - The city plans to complete over 200 merger and acquisition projects with a total transaction value exceeding 100 billion yuan by 2027 [1] Group 2: Industry Performance - Shanghai's manufacturing output in the three leading industries grew by 8.5% year-on-year, with artificial intelligence manufacturing increasing by 12.8% [2] - The overall industrial output value in Shanghai increased by 5.7% year-on-year, with strategic emerging industries growing by 7.3% [2] Group 3: Company Announcements - UBI, a major shareholder of Shenyang Biological, plans to reduce its stake by up to 3% due to funding needs for clinical trials and commercialization of new drugs [8] - Sanwang Communication intends to repurchase shares worth between 20 million and 40 million yuan to support employee stock ownership plans [9] - Zhongjuxin reported a net profit increase of 152.24% year-on-year for the third quarter, with total revenue of 314 million yuan [10] Group 4: Financing Activities - Leju Robotics completed a Pre-IPO round of financing amounting to 1.5 billion yuan, with plans for an IPO underway [14] - Xunyu Technology announced over 100 million yuan in Pre-A round financing led by Sequoia China and Hillhouse Capital [15] - Haibo Pharmaceutical completed over 200 million yuan in B round financing, focusing on small molecule targeted drug development [18]

Core Viewpoint - UBI, a major shareholder of Shenlian Bio, plans to reduce its stake in the company to fund clinical trials and commercialization of its Alzheimer's peptide vaccine and related manufacturing base in China [1] Shareholder Reduction Plan - UBI intends to reduce its holdings by selling 4,106,440 shares through centralized bidding on the Shanghai Stock Exchange, which represents up to 1.00% of the total shares [1] - Additionally, UBI plans to sell 8,212,880 shares via block trading, accounting for up to 2.00% of the total shares [1] - The share reduction will occur within three months after a 15 trading day period following the announcement and will be at market price, not lower than the initial public offering price [1]

智通财经APP讯，申联生物(688098.SH)发布公告，美国联合生物医药公司(UNITED BIOMEDICAL, INC. 简称"UBI")因推进其阿尔茨海默症合成肽疫苗等原研创新药的临床试验、商业化布局及与中国的 合作伙伴加速与合成肽有关的生产制造基地的建设等而需资金投入，拟自公告披露之日起15个交易日之 后的3个月内以通过上海证券交易所交易系统以集中竞价交易方式减持公司股份410.64万股，不超过公 司股份总数的1%;以大宗交易方式减持公司股份821.29万股，不超过公司股份总数的2%。 ...

Core Viewpoint - The company Shenyuan Biological (688098.SH) announced that its shareholder UBI plans to reduce its stake in the company to fund clinical trials and commercialization of its Alzheimer's peptide vaccine and to accelerate the construction of a manufacturing base in collaboration with Chinese partners [1] Group 1 - UBI intends to reduce its holdings by 4.1064 million shares through centralized bidding on the Shanghai Stock Exchange, which accounts for no more than 1.00% of the company's total shares [1] - Additionally, UBI plans to sell 8.2129 million shares through block trading, representing no more than 2.00% of the company's total shares [1] - The share reduction will be conducted at market prices, not lower than the company's initial public offering price [1]

Core Viewpoint - UBI, a shareholder holding 10.52% of Shenyuan Biological (688098), plans to reduce its stake due to funding needs for clinical trials and commercialization of its Alzheimer's peptide vaccine and related manufacturing base in China [1] Group 1: Shareholder Actions - UBI intends to reduce its holdings by up to 4.1064 million shares through centralized bidding, representing 1% of the total share capital [1] - Additionally, UBI plans to reduce its holdings by up to 8.2129 million shares through block trading, accounting for 2% of the total share capital [1]

证券代码：688098 证券简称：申联生物 公告编号：2025-037 申联生物医药(上海)股份有限公司 持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 股东持股的基本情况 截至本公告披露日，美国联合生物医药公司（UNITED BIOMEDICAL, INC. 以下简称"UBI"）持有申联生物医药（上海）股份有限公司（以下简称"公司" 或"申联生物"）43,199,898 股股份，占公司总股本的 10.52%。上述股份来源为 公司首次公开发行股票并上市前取得，且已于 2020 年 10 月 28 日后上市流通。 减持计划的主要内容 股东 UBI 因推进其阿尔茨海默症合成肽疫苗等原研创新药的临床试验、商 业化布局及与中国的合作伙伴加速与合成肽有关的生产制造基地的建设等而需 资金投入，拟自本公告披露之日起 15 个交易日之后的 3 个月内以通过上海证券 交易所交易系统以集中竞价交易方式减持本公司股份 4,106,440 股，不超过本公 司股份总数的 1.00%；以大 ...

Core Points - The core point of the announcement is that United BioPharma, a US-based company, holds 43.1999 million shares of Shenlian Bio, accounting for 10.52% of the total shares [1] Summary by Category Shareholding and Reduction Plan - United BioPharma plans to reduce its holdings due to funding needs, with a proposed reduction period from November 13, 2025, to February 12, 2026 [1] - The company intends to sell up to 4.1064 million shares through centralized bidding, representing 1.00% of the total shares [1] - Additionally, it plans to reduce up to 8.2129 million shares through block trading, which accounts for 2.00% of the total shares [1] - The total reduction will not exceed 12.3193 million shares, which is a maximum of 3% of the total shares, all of which were acquired before the IPO [1]

Core Viewpoint - UBI, a major shareholder of Shenlian Bio, plans to reduce its stake by up to 3% to fund clinical trials and commercialization of innovative drugs, including an Alzheimer's peptide vaccine [1] Summary by Categories Shareholder Actions - UBI intends to reduce its holdings by a total of up to 12,319,300 shares, which represents 3% of Shenlian Bio's total share capital [1] - The reduction will occur through two methods: a centralized bidding transaction for up to 4,106,400 shares and a block trade for up to 8,212,900 shares [1] Timeline - The planned reduction period is from November 13, 2025, to February 12, 2026 [1] Purpose of Reduction - The funds from the share reduction will be used to support the clinical trials and commercialization of the Alzheimer's peptide vaccine and to accelerate the construction of manufacturing bases in collaboration with partners in China [1]

Core Viewpoint - The animal health sector experienced a decline of 0.36% on October 22, with Dayu Biological leading the drop. The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1]. Stock Performance Summary - The following stocks in the animal health sector showed varied performance: - Shengwu Co. (600201) closed at 10.78, up 0.56% with a trading volume of 327,000 shares and a turnover of 351 million yuan - Ruipu Biological (300119) closed at 21.50, up 0.51% with a trading volume of 73,200 shares and a turnover of 158 million yuan - Haili Biological (603718) closed at 7.04, up 0.28% with a trading volume of 44,200 shares and a turnover of 31.17 million yuan - Dayu Biological (920970) closed at 9.46, down 1.25% with a trading volume of 20,800 shares and a turnover of 19.89 million yuan - ST Lvkang (002868) closed at 28.49, down 1.18% with a trading volume of 9,904 shares and a turnover of 28.26 million yuan [1][2]. Capital Flow Analysis - The animal health sector saw a net outflow of 47.45 million yuan from institutional investors, while retail investors contributed a net inflow of 36.66 million yuan. Speculative funds recorded a net inflow of 10.80 million yuan [2][3]. - Specific stock capital flows included: - Shunlian Biological (688098) had a net inflow of 6.94 million yuan from institutional investors but a net outflow of 12.58 million yuan from retail investors - Ruipu Biological (300119) experienced a net outflow of 2.94 million yuan from institutional investors, with a significant net inflow of 13.74 million yuan from speculative funds [3].

Core Viewpoint - The animal health sector experienced a slight decline of 0.02% on October 21, with Bioworks leading the drop. Meanwhile, the Shanghai Composite Index rose by 1.36% and the Shenzhen Component Index increased by 2.06% [1]. Group 1: Market Performance - The animal health sector's performance was mixed, with individual stocks showing varying degrees of increase and decrease. Notably, the top gainers included: - Driving Force (4.50% increase) [1] - Dayu Biological (3.46% increase) [1] - Yongshun Biological (2.06% increase) [1] - Conversely, Bioworks saw a decline of 2.10%, leading the losses in the sector [2]. Group 2: Trading Volume and Capital Flow - The trading volume for the animal health sector indicated a net outflow of 151 million yuan from institutional investors, while retail investors saw a net inflow of 116 million yuan [2]. - The capital flow for individual stocks showed significant movements, with: - Key stock, Bioworks, experiencing a net outflow of 6.46 million yuan from institutional investors [3]. - Retail investors contributed a net inflow of 7.59 million yuan to Zhongmu Co. [3]. Group 3: Individual Stock Analysis - The following stocks had notable capital flows: - KQ Biological had a net inflow of 1.83 million yuan from institutional investors [3]. - ST Green Health faced a net outflow of 4.37 million yuan from institutional investors [3]. - The stock of Rui Pu Biological saw a net inflow of 17.22 million yuan from retail investors despite a net outflow from institutional investors [3].